{"id":1822,"date":"2025-11-17T06:01:23","date_gmt":"2025-11-17T06:01:23","guid":{"rendered":"https:\/\/bloodsense.ai\/diseases\/lou-gehrigs-disease-symptoms-causes-and-treatments\/"},"modified":"2026-08-07T01:02:04","modified_gmt":"2026-08-07T01:02:04","slug":"%e6%b8%90%e5%86%bb%e7%97%87%e7%9a%84%e7%97%87%e7%8a%b6%e3%80%81%e7%97%85%e5%9b%a0%e5%92%8c%e6%b2%bb%e7%96%97","status":"publish","type":"post","link":"https:\/\/bloodsense.ai\/zh_cn\/%e7%96%be%e7%97%85\/%e6%b8%90%e5%86%bb%e7%97%87%e7%9a%84%e7%97%87%e7%8a%b6%e3%80%81%e7%97%85%e5%9b%a0%e5%92%8c%e6%b2%bb%e7%96%97\/","title":{"rendered":"Lou Gehrig’s Disease (ALS): Symptoms, Causes, and Treatments"},"content":{"rendered":"

Amyotrophic lateral sclerosis, widely known as ALS or Lou Gehrig’s disease, is a progressive disease that gradually destroys the nerve cells controlling voluntary muscle movement. Over time it affects walking, speaking, swallowing, and eventually breathing, while thinking and the senses are often preserved. There is no cure yet, and ALS remains a serious diagnosis, but research is moving quickly: the first therapy targeting a genetic cause was approved in 2023, and blood-based tools are beginning to speed diagnosis. This guide explains what ALS is, its symptoms, causes, how it is diagnosed, the treatments and supportive care that help people live as well as possible, and the latest scientific advances.<\/p>\n\n

What is ALS (Lou Gehrig’s disease)?<\/h2>\n

ALS is a neurodegenerative disease in which the motor neurons, the nerve cells in the brain and spinal cord that tell muscles to move, progressively break down and die. As these cells are lost, the brain can no longer control voluntary movement, and muscles weaken and waste away. The name is descriptive: “amyotrophic” refers to muscle wasting, and “lateral sclerosis” to hardening in the parts of the spinal cord affected. It is called Lou Gehrig’s disease after the baseball player diagnosed with it in 1939.<\/p>\n

ALS\u901a\u5e38\u572860\u81f380\u5c81\u4e4b\u95f4\u53d1\u75c5\uff0c\u7f8e\u56fd\u6bcf\u5e74\u7ea6\u67095,000\u4eba\u88ab\u786e\u8bca\u3002\u8be5\u75c5\u5448\u8fdb\u884c\u6027\u53d1\u5c55\uff0c\u5927\u591a\u6570\u60a3\u8005\u5728\u75c7\u72b6\u51fa\u73b0\u540e\u5b58\u6d3b\u7ea63\u81f35\u5e74\uff0c\u6700\u5e38\u89c1\u7684\u6b7b\u56e0\u662f\u8d1f\u8d23\u547c\u5438\u7684\u808c\u8089\u9010\u6e10\u8870\u5f31\uff1b\u4f46\u7ea6\u5341\u5206\u4e4b\u4e00\u7684\u60a3\u8005\u53ef\u5b58\u6d3b10\u5e74\u6216\u66f4\u957f\u65f6\u95f4\uff0c\u75c5\u7a0b\u56e0\u4eba\u800c\u5f02\u3002\u91cd\u8981\u7684\u662f\uff0cALS\u4e0d\u5177\u6709\u4f20\u67d3\u6027\u3002<\/p>\n\n

ALS\u7684\u75c7\u72b6<\/h2>\n

ALS\u901a\u5e38\u8d77\u75c5\u9690\u533f\uff0c\u6700\u521d\u53ea\u5f71\u54cd\u8eab\u4f53\u67d0\u4e00\u90e8\u4f4d\uff0c\u4e4b\u540e\u9010\u6e10\u6269\u6563\u3002\u65e9\u671f\u75c7\u72b6\u5e38\u89c1\u808c\u8089\u98a4\u52a8\uff08\u79f0\u4e3a\u808c\u675f\u9707\u98a4\uff09\uff0c\u4ee5\u53ca\u808c\u8089\u75c9\u631b\u3001\u50f5\u786c\u548c\u65e0\u529b\uff0c\u6700\u521d\u5f80\u5f80\u51fa\u73b0\u5728\u624b\u90e8\u3001\u624b\u81c2\u6216\u817f\u90e8\uff0c\u6216\u8d1f\u8d23\u8bf4\u8bdd\u548c\u541e\u54bd\u7684\u808c\u8089\u3002\u7531\u4e8e\u65e9\u671f\u75c7\u72b6\u8f83\u8f7b\u5fae\uff0cALS\u6709\u65f6\u4f1a\u5728\u521d\u671f\u88ab\u8bef\u8bca\u4e3a\u5176\u4ed6\u75be\u75c5\u3002<\/p>\n

\u968f\u7740\u75c5\u60c5\u8fdb\u5c55\uff0c\u808c\u8089\u65e0\u529b\u8303\u56f4\u4e0d\u65ad\u6269\u5927\u3001\u7a0b\u5ea6\u4e0d\u65ad\u52a0\u6df1\uff0c\u5bfc\u81f4\u884c\u8d70\u56f0\u96be\u3001\u624b\u90e8\u6d3b\u52a8\u53d7\u9650\u3001\u8bf4\u8bdd\u4e0d\u6e05\u3001\u5480\u56bc\u548c\u541e\u54bd\u56f0\u96be\u3002\u6700\u7ec8\uff0c\u63a7\u5236\u547c\u5438\u7684\u808c\u8089\u4e5f\u4f1a\u53d7\u5230\u5f71\u54cd\uff0c\u8fd9\u662f\u6700\u4e25\u91cd\u7684\u5e76\u53d1\u75c7\u3002\u5927\u591a\u6570\u60a3\u8005\u7684\u611f\u89c9\u529f\u80fd\u4ee5\u53ca\u601d\u7ef4\u548c\u8bb0\u5fc6\u80fd\u529b\u57fa\u672c\u4fdd\u6301\u5b8c\u597d\uff0c\u4f46\u5c11\u6570\u60a3\u8005\u4f1a\u51fa\u73b0\u601d\u7ef4\u6216\u884c\u4e3a\u65b9\u9762\u7684\u53d8\u5316\u3002\u8bc6\u522b\u8fdb\u884c\u6027\u3001\u65e0\u75db\u6027\u808c\u8089\u65e0\u529b\u7684\u89c4\u5f8b\uff0c\u662f\u5c3d\u65e9\u5c31\u533b\u8bc4\u4f30\u7684\u5173\u952e\u3002<\/p>\n\n

ALS\u7684\u75c5\u56e0<\/h2>\n

\u5927\u591a\u6570\u60a3\u8005\u7684ALS\u75c5\u56e0\u5c1a\u4e0d\u660e\u786e\u3002\u7ea690%\u81f395%\u7684\u75c5\u4f8b\u4e3a\u6563\u53d1\u6027\uff0c\u5373\u65e0\u5bb6\u65cf\u75c5\u53f2\uff1b\u53e6\u67095%\u81f310%\u4e3a\u5bb6\u65cf\u6027\uff0c\u5177\u6709\u5bb6\u65cf\u9057\u4f20\u503e\u5411\uff0c\u4e0e\u7279\u5b9a\u57fa\u56e0\u53d8\u5f02\u76f8\u5173\u3002\u76ee\u524d\u6700\u53d7\u5173\u6ce8\u7684\u4e24\u4e2a\u57fa\u56e0\u662fC9orf72\uff08\u6700\u5e38\u89c1\u7684\u9057\u4f20\u75c5\u56e0\uff09\u548cSOD1\uff0c\u540e\u8005\u5bf9\u6cbb\u7597\u5177\u6709\u91cd\u8981\u610f\u4e49\uff0c\u56e0\u4e3a\u76ee\u524d\u5df2\u6709\u4e00\u79cd\u7597\u6cd5\u53ef\u76f4\u63a5\u9776\u5411\u8be5\u57fa\u56e0\u3002<\/p>\n

\u7814\u7a76\u4eba\u5458\u8ba4\u4e3a\uff0cALS\u662f\u9057\u4f20\u6613\u611f\u6027\u4e0e\u5176\u4ed6\u56e0\u7d20\u5171\u540c\u4f5c\u7528\u7684\u7ed3\u679c\uff0c\u8fd9\u4e9b\u56e0\u7d20\u4f1a\u968f\u65f6\u95f4\u63a8\u79fb\u635f\u4f24\u8fd0\u52a8\u795e\u7ecf\u5143\uff0c\u5305\u62ec\u795e\u7ecf\u7ec6\u80de\u5185\u7684\u86cb\u767d\u8d28\u5904\u7406\u969c\u788d\u548c\u708e\u75c7\u53cd\u5e94\u3002\u5bf9\u4e8e\u6709ALS\u6216\u76f8\u5173\u75be\u75c5\u5bb6\u65cf\u53f2\u7684\u4eba\uff0c\u5efa\u8bae\u8fdb\u884c\u57fa\u56e0\u68c0\u6d4b\uff1b\u82e5\u8981\u786e\u5b9a\u662f\u5426\u7b26\u5408SOD1\u9776\u5411\u7597\u6cd5\u7684\u9002\u7528\u6761\u4ef6\uff0c\u57fa\u56e0\u68c0\u6d4b\u4e5f\u662f\u5fc5\u8981\u6b65\u9aa4\u3002\u4f46\u5bf9\u4e8e\u5927\u591a\u6570\u65e0\u5bb6\u65cf\u53f2\u7684\u60a3\u8005\u800c\u8a00\uff0cALS\u7684\u53d1\u75c5\u539f\u56e0\u65e0\u6cd5\u8ffd\u6eaf\u81f3\u5355\u4e00\u56e0\u7d20\u3002<\/p>\n\n

ALS\u7684\u8bca\u65ad\u65b9\u5f0f<\/h2>\n

\u76ee\u524d\u6ca1\u6709\u4efb\u4f55\u5355\u4e00\u68c0\u6d4b\u53ef\u4ee5\u786e\u8bca\u808c\u840e\u7f29\u4fa7\u7d22\u786c\u5316\u75c7\uff08ALS\uff09\uff0c\u56e0\u6b64\u8bca\u65ad\u4e3b\u8981\u4f9d\u9760\u4e34\u5e8a\u5224\u65ad\uff0c\u5373\u901a\u8fc7\u795e\u7ecf\u7cfb\u7edf\u68c0\u67e5\u53d1\u73b0\u8fdb\u884c\u6027\u808c\u8089\u65e0\u529b\uff0c\u540c\u65f6\u5b58\u5728\u4e0a\u8fd0\u52a8\u795e\u7ecf\u5143\u548c\u4e0b\u8fd0\u52a8\u795e\u7ecf\u5143\u53d7\u635f\u7684\u4f53\u5f81\uff0c\u5e76\u7ed3\u5408\u76f8\u5173\u68c0\u67e5\u6392\u9664\u5176\u4ed6\u53ef\u80fd\u51fa\u73b0\u7c7b\u4f3c\u75c7\u72b6\u7684\u75be\u75c5\u3002\u808c\u7535\u56fe\u548c\u795e\u7ecf\u4f20\u5bfc\u68c0\u67e5\u53ef\u6d4b\u91cf\u808c\u8089\u4e0e\u795e\u7ecf\u7684\u7535\u6d3b\u52a8\uff0c\u662f\u652f\u6301\u8bca\u65ad\u7684\u6838\u5fc3\u624b\u6bb5\uff1b\u6838\u78c1\u5171\u632f\uff08MRI\uff09\u548c\u8840\u6db2\u68c0\u67e5\u5219\u6709\u52a9\u4e8e\u6392\u9664\u5176\u4ed6\u75c5\u56e0\u3002<\/p>\n

\u4e24\u9879\u8fdb\u5c55\u6b63\u5728\u4f7f\u8bca\u65ad\u53d8\u5f97\u66f4\u5feb\u3001\u66f4\u53ef\u9760\u30022020\u5e74\u63d0\u51fa\u7684\"\u9ec4\u91d1\u6d77\u5cb8\u6807\u51c6\"\u7b80\u5316\u4e86ALS\u7684\u8bca\u65ad\u6807\u51c6\uff1b\u4e00\u79cd\u53cd\u6620\u795e\u7ecf\u635f\u4f24\u7684\u8840\u6db2\u6807\u5fd7\u7269\u2014\u2014\u795e\u7ecf\u4e1d\u8f7b\u94fe\u86cb\u767d\u2014\u2014\u4e5f\u8d8a\u6765\u8d8a\u591a\u5730\u88ab\u7528\u4e8e\u8f85\u52a9\u8bca\u65ad\u548c\u8ffd\u8e2a\u75c5\u60c5\u8fdb\u5c55\uff0c\u56e0\u4e3aALS\u60a3\u8005\u7684\u8be5\u6307\u6807\u6c34\u5e73\u901a\u5e38\u660e\u663e\u504f\u9ad8\u3002\u5728\u6392\u9664\u808c\u8089\u75be\u75c5\u7684\u8fc7\u7a0b\u4e2d\uff0c\u533b\u751f\u8fd8\u53ef\u80fd\u68c0\u6d4b\u808c\u9178\u6fc0\u9176\u7b49\u808c\u8089\u9176\u6307\u6807\uff0c\u4e86\u89e3 CPK\u68c0\u67e5\u6240\u6d4b\u5b9a\u7684\u808c\u9178\u6fc0\u9176\u6c34\u5e73<\/a> \u6709\u52a9\u4e8e\u60a8\u7406\u89e3\u8fd9\u4e00\u6b65\u9aa4\u3002\u7531\u4e8e\u591a\u79cd\u75be\u75c5\u53ef\u5f15\u8d77\u76f8\u4f3c\u7684\u808c\u8089\u65e0\u529b\u75c7\u72b6\uff0c\u4e34\u5e8a\u533b\u751f\u9700\u8981\u5c06ALS\u4e0e\u5176\u4ed6\u75be\u75c5\u52a0\u4ee5\u533a\u5206\uff0c\u4f8b\u5982 \u91cd\u75c7\u808c\u65e0\u529b\u6240\u5bfc\u81f4\u7684\u795e\u7ecf\u808c\u8089\u63a5\u5934\u529f\u80fd\u969c\u788d<\/a> \u548c \u591a\u53d1\u6027\u786c\u5316\u75c7\u6240\u5bfc\u81f4\u7684\u795e\u7ecf\u9ad3\u9798\u635f\u4f24<\/a>\u3002\u4e86\u89e3 \u5982\u4f55\u8bfb\u61c2\u5316\u9a8c\u62a5\u544a\u4e2d\u7684\u6807\u8bb0\u548c\u53c2\u8003\u8303\u56f4<\/a> \u6709\u52a9\u4e8e\u7406\u89e3\u8fd9\u4e9b\u68c0\u67e5\u7684\u610f\u4e49\u3002<\/p>\n\n

ALS\u7684\u6cbb\u7597\u65b9\u6848<\/h2>\n

\u76ee\u524dALS\u5c1a\u65e0\u6839\u6cbb\u65b9\u6cd5\uff0c\u4f46\u6cbb\u7597\u53ef\u5728\u4e00\u5b9a\u7a0b\u5ea6\u4e0a\u5ef6\u7f13\u90e8\u5206\u60a3\u8005\u7684\u75c5\u60c5\u8fdb\u5c55\u3001\u7f13\u89e3\u75c7\u72b6\u5e76\u6539\u5584\u751f\u6d3b\u8d28\u91cf\uff0c\u591a\u5b66\u79d1\u7efc\u5408\u8bca\u7597\u662f\u6cbb\u7597\u7684\u57fa\u7840\u3002\u5229\u9c81\u5511\u548c\u4f9d\u8fbe\u62c9\u5949\u4e24\u79cd\u836f\u7269\u53ef\u9002\u5ea6\u5ef6\u7f13\u75be\u75c5\u8fdb\u5c55\u6216\u529f\u80fd\u4e0b\u964d\uff1b\u9488\u5bf9\u7279\u5b9a\u9057\u4f20\u6027ALS\uff0c\u76ee\u524d\u4e5f\u6709\u4e00\u79cd\u65b0\u578b\u57fa\u56e0\u9776\u5411\u7597\u6cd5\u53ef\u4f9b\u9009\u62e9\u3002<\/p>\n\n

\n
\u6cbb\u7597\u65b9\u5f0f<\/th>\u4f5c\u7528<\/th><\/tr><\/thead>
\u5229\u9c81\u5511<\/td>\u53e3\u670d\u836f\u7269\uff0c\u53ef\u80fd\u5c06\u751f\u5b58\u671f\u5ef6\u957f\u6570\u6708<\/td><\/tr>\n
\u4f9d\u8fbe\u62c9\u5949<\/td>\u5bf9\u90e8\u5206\u60a3\u8005\u53ef\u5ef6\u7f13\u65e5\u5e38\u529f\u80fd\u7684\u4e0b\u964d<\/td><\/tr>\n
\u6258\u592b\u68ee<\/td>\u9488\u5bf9SOD1\u57fa\u56e0\u7a81\u53d8\u9057\u4f20\u6027ALS\u7684\u57fa\u56e0\u9776\u5411\u7597\u6cd5<\/td><\/tr>\n
\u652f\u6301\u6027\u62a4\u7406<\/td>\u7269\u7406\u6cbb\u7597\u3001\u804c\u4e1a\u6cbb\u7597\u3001\u8a00\u8bed\u6cbb\u7597\u3001\u8425\u517b\u652f\u6301\u53ca\u547c\u5438\u8f85\u52a9<\/td><\/tr>\n<\/tbody><\/table><\/figure>\n\n

\u9664\u836f\u7269\u6cbb\u7597\u5916\uff0c\u7531\u795e\u7ecf\u79d1\u533b\u751f\u3001\u5404\u7c7b\u6cbb\u7597\u5e08\u3001\u547c\u5438\u4e0e\u8425\u517b\u4e13\u79d1\u533b\u751f\u4ee5\u53ca\u5fc3\u7406\u5065\u5eb7\u652f\u6301\u4eba\u5458\u7ec4\u6210\u7684\u534f\u4f5c\u56e2\u961f\uff0c\u80fd\u591f\u5e2e\u52a9\u60a3\u8005\u7ba1\u7406\u75c7\u72b6\u3001\u7ef4\u6301\u72ec\u7acb\u751f\u6d3b\u80fd\u529b\u548c\u751f\u6d3b\u8212\u9002\u5ea6\u3002\u8f85\u52a9\u6c9f\u901a\u3001\u79fb\u52a8\u548c\u547c\u5438\u7684\u5404\u7c7b\u8bbe\u5907\uff08\u5982\u65e0\u521b\u901a\u6c14\uff09\u53ef\u663e\u8457\u6539\u5584\u751f\u6d3b\u8d28\u91cf\uff0c\u547c\u5438\u652f\u6301\u8fd8\u6709\u52a9\u4e8e\u5ef6\u957f\u751f\u5b58\u671f\u3002\u8fd9\u4e00\u9886\u57df\u4e5f\u5728\u4e0d\u65ad\u4ece\u632b\u6298\u4e2d\u6c72\u53d6\u7ecf\u9a8c\u2014\u2014\u4f8b\u59822024\u5e74\u67d0\u836f\u7269\u56e0\u66f4\u5927\u89c4\u6a21\u8bd5\u9a8c\u672a\u80fd\u8bc1\u5b9e\u5176\u7597\u6548\u800c\u64a4\u5e02\uff0c\u8fd9\u518d\u6b21\u51f8\u663e\u4e86\u4e25\u683c\u4e34\u5e8a\u9a8c\u8bc1\u7684\u91cd\u8981\u6027\u3002<\/p>\n\n

\u4e0eALS\u5171\u5b58\u53ca\u957f\u671f\u9884\u540e<\/h2>\n

ALS\u5bf9\u6bcf\u4e2a\u4eba\u7684\u5f71\u54cd\u5404\u4e0d\u76f8\u540c\u3002\u5c3d\u7ba1\u8fd9\u662f\u4e00\u79cd\u4e25\u91cd\u7684\u8fdb\u884c\u6027\u75be\u75c5\uff0c\u4f46\u901a\u8fc7\u5408\u7406\u89c4\u5212\u548c\u5168\u9762\u62a4\u7406\uff0c\u60a3\u8005\u4ecd\u53ef\u5c3d\u53ef\u80fd\u5145\u5b9e\u3001\u8212\u9002\u5730\u751f\u6d3b\u3002\u62a4\u7406\u7684\u91cd\u70b9\u5728\u4e8e\u7ef4\u6301\u8eab\u4f53\u529f\u80fd\u3001\u63a7\u5236\u808c\u8089\u75c9\u631b\u3001\u553e\u6db2\u5206\u6ccc\u8fc7\u591a\u53ca\u541e\u54bd\u56f0\u96be\u7b49\u75c7\u72b6\uff0c\u5e76\u968f\u7740\u75c5\u60c5\u53d8\u5316\u63d0\u4f9b\u547c\u5438\u548c\u8425\u517b\u652f\u6301\u3002\u5bf9\u60a3\u8005\u672c\u4eba\u53ca\u5176\u7167\u62a4\u8005\u7684\u60c5\u611f\u652f\u6301\u548c\u5b9e\u9645\u5e2e\u52a9\uff0c\u662f\u4e0eALS\u5171\u540c\u751f\u6d3b\u7684\u91cd\u8981\u7ec4\u6210\u90e8\u5206\u3002<\/p>\n

Because the disease progresses, care teams help with proactive planning around communication tools, mobility equipment, and decisions about breathing support, always guided by the person’s own wishes and values. Support organizations and specialized ALS clinics provide resources that improve both quality and length of life, and ongoing research continues to expand what is possible.<\/p>\n\n

ALS\u7814\u7a76\u7684\u6700\u65b0\u79d1\u5b66\u8fdb\u5c55<\/h2>\n

ALS\u7684\u6cbb\u7597\u3001\u8bca\u65ad\u548c\u751f\u7269\u6807\u5fd7\u7269\u7814\u7a76\u6b63\u5728\u540c\u6b65\u63a8\u8fdb\u3002\u6839\u636ePubMed\u6536\u5f55\u7684\u7814\u7a76\uff0c2026\u5e74\u53d1\u8868\u4e8e\u300aJAMA\u795e\u7ecf\u75c5\u5b66\u300b\u7684\u4e00\u9879\u7814\u7a76\u5bf9\u63a5\u53d7\u57fa\u56e0\u9776\u5411\u836f\u7269\u6258\u592b\u68ee\uff08tofersen\uff09\u6cbb\u7597\u7684SOD1\u578bALS\u60a3\u8005\u7684\u7ec4\u7ec7\u8fdb\u884c\u4e86\u5206\u6790\uff0c\u53d1\u73b0\u8be5\u836f\u7269\u80fd\u591f\u5230\u8fbe\u810a\u9ad3\u548c\u5927\u8111\uff0c\u5e76\u663e\u8457\u964d\u4f4e\u6709\u5bb3\u7684SOD1\u86cb\u767d\u6c34\u5e73\uff08Guise\u7b49\uff0c2026\u5e74\uff09\u3002\u8fd9\u5bf9\u60a8\u610f\u5473\u7740\u4ec0\u4e48\uff1a\u8fd9\u662f\u76f4\u63a5\u6765\u81ea\u4eba\u4f53\u7684\u8bc1\u636e\uff0c\u8bc1\u660e\u9996\u4e2a\u57fa\u56e0\u9776\u5411ALS\u7597\u6cd5\u786e\u5b9e\u80fd\u5728\u795e\u7ecf\u7cfb\u7edf\u4e2d\u4f5c\u7528\u4e8e\u5176\u9776\u70b9\uff0c\u8fdb\u4e00\u6b65\u51f8\u663e\u4e86\u57fa\u56e0\u68c0\u6d4b\u5728\u7b5b\u9009\u6f5c\u5728\u83b7\u76ca\u4eba\u7fa4\u65b9\u9762\u7684\u91cd\u8981\u4ef7\u503c\u3002<\/p>\n

A 2026 study in Muscle & Nerve reported that adding the blood biomarker neurofilament light chain to the standard diagnostic criteria sharply improved the ability to predict who would go on to have definite ALS (Smith et al., 2026). What this means for you: a simple blood test used alongside the exam and nerve studies could help doctors reach a diagnosis earlier and with more certainty, addressing a delay many people experience. On the treatment front, a 2026 phase 2b trial in JAMA Neurology of an investigational oral drug called PrimeC found slower functional decline and a lower risk of hospitalization, respiratory failure, or death with continuous treatment (Cudkowicz et al., 2026). What this means for you: it is an early but encouraging signal that supports a larger confirmatory trial of a potential new option alongside existing therapies.<\/p>\n\n

ALS\u6838\u5fc3\u672f\u8bed\u8bcd\u6c47\u8868<\/h2>\n
\n
\u672f\u8bed<\/th>\u5b9a\u4e49<\/th><\/tr><\/thead>
\u8fd0\u52a8\u795e\u7ecf\u5143<\/td>\u5c06\u4fe1\u53f7\u4ece\u5927\u8111\u548c\u810a\u9ad3\u4f20\u9012\u81f3\u808c\u8089\u7684\u795e\u7ecf\u7ec6\u80de\u3002<\/td><\/tr>\n
\u808c\u675f\u9707\u98a4<\/td>\u7ec6\u5c0f\u7684\u4e0d\u81ea\u4e3b\u808c\u8089\u62bd\u52a8\uff0c\u662fALS\u5e38\u89c1\u7684\u65e9\u671f\u8868\u73b0\u3002<\/td><\/tr>\n
\u6563\u53d1\u6027ALS<\/td>\u65e0\u5bb6\u65cf\u75c5\u53f2\u7684ALS\uff0c\u5360\u7edd\u5927\u591a\u6570\u75c5\u4f8b\u3002<\/td><\/tr>\n
\u5bb6\u65cf\u6027ALS<\/td>\u4e0e\u7279\u5b9a\u57fa\u56e0\u53d8\u5f02\uff08\u5982C9orf72\u6216SOD1\uff09\u76f8\u5173\u7684\u9057\u4f20\u6027ALS\u3002<\/td><\/tr>\n
\u808c\u7535\u56fe<\/td>\u4e00\u79cd\u68c0\u6d4b\u808c\u8089\u7535\u6d3b\u52a8\u7684\u68c0\u67e5\uff0c\u7528\u4e8e\u8f85\u52a9\u8bca\u65adALS\u3002<\/td><\/tr>\n
\u795e\u7ecf\u4e1d\u8f7b\u94fe<\/td>\u8840\u6db2\u548c\u8111\u810a\u6db2\u4e2d\u53cd\u6620\u795e\u7ecf\u635f\u4f24\u7684\u6807\u5fd7\u7269\uff0c\u5728ALS\u60a3\u8005\u4e2d\u6c34\u5e73\u5347\u9ad8\u3002<\/td><\/tr>\n
\u65e0\u521b\u901a\u6c14<\/td>\u901a\u8fc7\u9762\u7f69\u63d0\u4f9b\u547c\u5438\u652f\u6301\uff0c\u6709\u52a9\u4e8e\u6539\u5584\u60a3\u8005\u7684\u8212\u9002\u5ea6\u548c\u751f\u5b58\u671f\u3002<\/td><\/tr>\n<\/tbody><\/table><\/figure>\n\n

\u5173\u4e8eALS\u7684\u5e38\u89c1\u95ee\u9898<\/h2>\n

\u4ec0\u4e48\u662fALS\uff1f<\/h3>\n

ALS\uff0c\u5373\u808c\u840e\u7f29\u4fa7\u7d22\u786c\u5316\u75c7\uff0c\u662f\u4e00\u79cd\u8fdb\u884c\u6027\u75be\u75c5\uff0c\u4f1a\u7834\u574f\u63a7\u5236\u968f\u610f\u808c\u8fd0\u52a8\u7684\u8fd0\u52a8\u795e\u7ecf\u5143\uff0c\u5bfc\u81f4\u56db\u80a2\u3001\u8a00\u8bed\u3001\u541e\u54bd\u529f\u80fd\u51cf\u9000\uff0c\u6700\u7ec8\u5f71\u54cd\u547c\u5438\u3002\u60a3\u8005\u7684\u601d\u7ef4\u80fd\u529b\u548c\u611f\u89c9\u901a\u5e38\u4e0d\u53d7\u5f71\u54cd\u3002\u76ee\u524d\u5c1a\u65e0\u6839\u6cbb\u65b9\u6cd5\uff0c\u4f46\u53ef\u901a\u8fc7\u836f\u7269\u548c\u652f\u6301\u6027\u62a4\u7406\u8fdb\u884c\u7ba1\u7406\u3002<\/p>\n

Is ALS the same as Lou Gehrig’s disease?<\/h3>\n

Yes. Lou Gehrig’s disease is another name for ALS, named after the baseball player diagnosed with it in 1939. The two terms refer to the same condition.<\/p>\n

ALS\u7684\u65e9\u671f\u8ff9\u8c61\u548c\u75c7\u72b6\u6709\u54ea\u4e9b\uff1f<\/h3>\n

\u65e9\u671f\u75c7\u72b6\u901a\u5e38\u5305\u62ec\u808c\u8089\u62bd\u52a8\u3001\u75c9\u631b\u3001\u50f5\u786c\u548c\u65e0\u529b\uff0c\u5e38\u4ece\u4e00\u53ea\u624b\u3001\u4e00\u6761\u624b\u81c2\u6216\u4e00\u6761\u817f\u5f00\u59cb\uff0c\u6216\u51fa\u73b0\u5728\u8d1f\u8d23\u8a00\u8bed\u548c\u541e\u54bd\u7684\u808c\u8089\u4e0a\u3002\u7531\u4e8e\u8fd9\u4e9b\u75c7\u72b6\u53ef\u80fd\u8f83\u4e3a\u9690\u533f\uff0c\u4e14\u4e0e\u5176\u4ed6\u75be\u75c5\u76f8\u4f3c\uff0c\u56e0\u6b64\u63a5\u53d7\u795e\u7ecf\u79d1\u533b\u751f\u7684\u8bc4\u4f30\u975e\u5e38\u91cd\u8981\u3002<\/p>\n

ALS\u7684\u75c5\u56e0\u662f\u4ec0\u4e48\uff1f\u5b83\u4f1a\u9057\u4f20\u5417\uff1f<\/h3>\n

\u5927\u591a\u6570\u808c\u840e\u7f29\u4fa7\u7d22\u786c\u5316\u75c7\uff08ALS\uff09\u5c5e\u4e8e\u6563\u53d1\u6027\uff0c\u65e0\u5df2\u77e5\u75c5\u56e0\u6216\u5bb6\u65cf\u53f2\u3002\u7ea65%\u81f310%\u4e3a\u5bb6\u65cf\u6027\uff0c\u4e0eC9orf72\u548cSOD1\u7b49\u57fa\u56e0\u53d8\u5f02\u6709\u5173\u3002\u5f53\u5b58\u5728\u5bb6\u65cf\u53f2\u65f6\uff0c\u5efa\u8bae\u8fdb\u884c\u57fa\u56e0\u68c0\u6d4b\uff1b\u82e5\u8981\u786e\u5b9a\u662f\u5426\u7b26\u5408SOD1\u9776\u5411\u6cbb\u7597\u7684\u9002\u7528\u6761\u4ef6\uff0c\u57fa\u56e0\u68c0\u6d4b\u4e5f\u662f\u5fc5\u8981\u7684\u3002<\/p>\n

\u786e\u8bcaALS\u540e\u7684\u9884\u671f\u5bff\u547d\u662f\u591a\u5c11\uff1f<\/h3>\n

\u5927\u591a\u6570\u60a3\u8005\u5728\u75c7\u72b6\u51fa\u73b0\u540e\u5b58\u6d3b\u7ea63\u81f35\u5e74\uff0c\u901a\u5e38\u56e0\u547c\u5438\u808c\u9010\u6e10\u65e0\u529b\u800c\u5bfc\u81f4\u6b7b\u4ea1\uff0c\u4f46\u7ea6\u5341\u5206\u4e4b\u4e00\u7684\u60a3\u8005\u53ef\u5b58\u6d3b10\u5e74\u6216\u66f4\u957f\u65f6\u95f4\u3002\u75c5\u7a0b\u56e0\u4eba\u800c\u5f02\uff0c\u547c\u5438\u652f\u6301\u548c\u8425\u517b\u652f\u6301\u6709\u52a9\u4e8e\u5ef6\u957f\u751f\u5b58\u65f6\u95f4\u5e76\u6539\u5584\u751f\u6d3b\u8d28\u91cf\u3002<\/p>\n

ALS\u6709\u6cbb\u6108\u65b9\u6cd5\u6216\u65b0\u7597\u6cd5\u5417\uff1f<\/h3>\n

\u76ee\u524d\u5c1a\u65e0\u6cbb\u6108\u65b9\u6cd5\uff0c\u4f46\u5229\u9c81\u5511\u548c\u4f9d\u8fbe\u62c9\u5949\u53ef\u5728\u4e00\u5b9a\u7a0b\u5ea6\u4e0a\u5ef6\u7f13\u75be\u75c5\u8fdb\u5c55\uff0c\u9488\u5bf9\u9057\u4f20\u6027SOD1\u578bALS\u7684\u57fa\u56e0\u9776\u5411\u7597\u6cd5\u6258\u592b\u68ee\uff08tofersen\uff09\u4e5f\u5df2\u4e0a\u5e02\u3002\u591a\u5b66\u79d1\u7efc\u5408\u652f\u6301\u6cbb\u7597\u81f3\u5173\u91cd\u8981\uff0c\u65b0\u7597\u6cd5\u7684\u7814\u7a76\u76ee\u524d\u4e5f\u5728\u79ef\u6781\u63a8\u8fdb\u4e2d\u3002<\/p>\n\n

\u53c2\u8003\u6765\u6e90<\/h2>\n